Risk-sharing agreements 

Risk-sharing models are becoming more common in the case of hospital-only medicines, while decisions on conditional reimbursement are stabilizing in the price and reimbursement processes of retail medicines. By means of risk-sharing agreements, the uncertainty about the cost and effectiveness of medicines can be divided and managed in a way that satisfies both parties. This will ultimately enable the drug to be used by patients in need.

By combining the wide-ranging expertise of Medaffcon and the management systems for risk-sharing models constructed by Tamro and hospital pharmacies (Tamro LINK), we can provide a comprehensive solution for the implementation of your risk-sharing models.


Our service concept includes that we:

  • design an optimal risk-sharing model from the perspective of both parties.
  • evaluate the cost-effectiveness of the selected model and the budget impact for both parties.
  • are responsible for the agreement negotiations with hospitals, providing a neutral expert view on what sort of a model could be acceptable for both parties.
  • organise the transfer of money and goods on a “turn-key” principle, regardless of whose distribution service is used (Tamro, Oriola, Magnum)


A successful risk-sharing agreement

  • helps the parties to work in a closer cooperation in the implementation and evaluation of a new form of treatment.
  • helps all parties evaluate and set the value for a new or existing form of treatment in a more precise manner.
  • decreases the risk of paying “too much”, for example in cases where the effectiveness of new forms of treatment is still a bit unsure – and it enables the faster implementation and use of such treatment with a more sustainable pricing model.
  • enables faster and more extensive market access of a new form of treatment.

”Risk sharing agreements aim to solve the classic pharmaceutical sales dilemma of who bears the risk of effectiveness and cost effectiveness related to the purchasing and using of medicines. We at Medaffcon execute risk-sharing agreements between the parties, ensuring that the agreements are operational and mutually beneficial. ”
Kalle Snicker
Sr. Market Access Manager, Medaffcon Oy

We are more than happy to tell you more!

Contact us

Our Risk-Sharing Agreements Experts:

Jarmo Hahl
Managing Director

Jarmo Hahl

Managing Director
M.Sc. (Economics)

+358 40 139 4001 LinkedIn

Jarmo joined Medaffcon as a partner and CEO in 2010, having previously worked in various expert and management positions in pharma companies for eight years. Jarmo has a degree in economics and before entering the pharmaceutical industry he held an office at the Turku School of Economics and also worked as a research fellow at Turku University Hospital.

Jarmo has strong expertise in new health technology innovations and how the demands and expectations of authorities, markets and customers are matched. He also brings to Medaffcon extensive experience in health economics and its applications in research and commercialization, as well as a broad understanding of the ever-changing operating environment. “From the access point of view, the Finnish health technology market is constantly becoming more demanding and therefore also more attractive from my point of view. On the other hand, increasing demands to demonstrate the effectiveness and cost-effectiveness of healthcare are broadening the scope and opportunities for Medaffcon to be involved in the development of healthcare as a whole.”

Kalle Snicker
Sr. Market Access Manager

Kalle Snicker

Sr. Market Access Manager

+358 40 052 6597 LinkedIn

Kalle Snicker joined Medaffcon’s team in September 2017. Kalle has a long history in the pharmaceutical industry. Along the years, he has gained experience in leading positions in sales and marketing, running the Baltic business unit, and in recent years, leading the oncology market access functions at Novartis Finland.

At Medaffcon, Kalle has been developing the introduction of hospital medicines, together with various pharmaceutical companies and authorities. In recent years, there has been a significant development in the introduction of hospital medicines, with the focus on the evaluation of medicines. The development and implementation of the evaluation are one of Kalle’s strongest competencies, which can benefit any actor in the industry.

Kalle’s strengths include his extensive and comprehensive view on how the industry functions as well as his ability to predict how future challenges can be considered and how the best possible result for the patient can be achieved in a new operational environment.